Completed NA INTERVENTIONAL 2-arm NCT00855439

Evaluation of Exenatide in Patients With Diabetic Neuropathy

A Single-center,Proof of Concept,Randomized,Controlled Parallel Group Clinical Trial of the Effects of Exenatide vs. a Long Acting Insulin Analog to Evaluate the Efficacy of Exenatide in Patients With Diabetic Neuropathy and Type 2 Diabetes

Sponsor: Amylin Pharmaceuticals, LLC.

Conditions Diabetic Peripheral Neuropathy Type 2 Diabetes Mellitus

Interventions Exenatide Glargine

Updated 5 times since 2017 Last updated: Jan 12, 2017 Started: Jun 30, 2008 Primary completion: May 31, 2014 Completion: May 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A NA clinical study on Diabetic Peripheral Neuropathy and Type 2 Diabetes Mellitus, this trial is completed. The trial is conducted by Amylin Pharmaceuticals, LLC. and has accumulated 5 data snapshots since 2008. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Jan 2021 — Jul 2024 [monthly]

Completed NA
Jun 2018 — Jan 2021 [monthly]

Completed NA
Jan 2017 — Jun 2018 [monthly]

Completed NA

First recorded

Jun 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Amylin Pharmaceuticals, LLC.
Eli Lilly and Company
University of Michigan

Data source: University of Michigan

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Ann Arbor, United States